Find in Library

629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor

oleh: Jameel Muzaffar, Tae Min Kim, Julie Brahmer, Dirk G Brockstedt, Chia-Chi Lin, Michael Chisamore, Ki Hyeong Lee, Paul D Kassner, Nuttapong Ngamphaiboon, William Ho, Nicole Nasrah, Pratibha Desai, Yin-Hsun Feng, Shang-Yin Wu, Rakesh Kumar Goyal